Guilin Sanjin(SZ:002275)2025-01-07 04:10Group 1: Company Performance and Expectations - The company has not yet disclosed its 2024 performance, with a report expected by the end of April 2025. Sales have been impacted by national policy adjustments, but the company is implementing measures to address this [2] - The current inventory levels are normal, maintained at approximately 1.5 to 2 months, which is lower than the same period last year [2] Group 2: Cost Management and Strategic Initiatives - The biopharmaceutical sector is facing challenges, with the company controlling costs and optimizing personnel structures to minimize losses from projects like Baofang and Baoshun [2] - The company is actively seeking partners for its biopharmaceutical segment and optimizing its R&D pipeline to focus on promising projects [2] Group 3: Future Plans and Shareholder Engagement - The company is looking for acquisition opportunities that align with its strategic development and can enhance corporate value [3] - The company intends to maintain its high dividend payout policy, ensuring stable cash flow to support operations and development [3] - The first employee stock ownership plan has been successful, and the company plans to refine its incentive mechanisms while considering other motivational strategies [3]